Transform practitioner and patient experience with an integrated precision medicine program
Healthcare leaders know that precision medicine improves quality of care but face implementation obstacles. IntelliSpace Genomics offers an intergrated genomics solution that works for your entire healthcare organization.
Why invest in a precision medicine program?
Molecular data in the clinical setting can have transformative impact by reducing cost of care and improving outcomes. Increased efficiencies and accuracy in reporting molecular diagnostics are critical to achieve the results that patients, pathologists and oncologists demand.
- $604 million in annual savings among all patients when Panitumamab or Cetuximab is limited to metastatic colorectal cancer patients whose KRAS gene is not mutated.1
- 74% reduction in the risk of death or disease progression in melanoma patients with BRAF V600E mutation when taking targeted therapy compared to standard of care.2
- 75% increase in personalized medicine investment by industry from 2006-2011.3
Genomic data is entering the healthcare continuum
IntelliSpace Genomics enables you to implement, integrate and scale your precision medicine program to improve patient outcomes and differentiate your organization.
Definitive Diagnosis: using multi-source diagnosis data to achieve personalized medicine
Choosing IntelliSpace Genomics means integrating molecular data into your existing data structure from day one.
By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.